Treatment of Urticaria in Breastfeeding Mothers

First-Line Treatment

The American College of Allergy, Asthma, and Immunology recommends starting with a second-generation non-sedating H1 antihistamine, such as cetirizine or loratadine, as these are the safest options during breastfeeding with minimal infant exposure through breast milk 1, 2, 3
Cetirizine 10 mg once daily or Loratadine 10 mg once daily is recommended as initial therapy for breastfeeding mothers with urticaria 1, 2, 3
Alternative second-generation options include desloratadine, fexofenadine, and levocetirizine 1, 3

If standard dosing provides inadequate symptom control after 24-48 hours, increase the antihistamine dose up to 4 times the standard dose when benefits outweigh risks, as supported by the Journal of Allergy and Clinical Immunology 4, 1, 3
Assess response after 2-4 weeks at standard dosing, and if symptoms are intolerable, escalation can occur earlier 4

For moderate to severe acute urticaria in breastfeeding mothers, add a short 3-day course of oral prednisolone 50 mg daily rather than waiting for antihistamine failure, as recommended by the American Academy of Allergy, Asthma, and Immunology 1
Prednisolone is preferred as it is 90% inactivated by the placenta and has minimal breast milk transfer 2

Apply cooling antipruritic lotions such as calamine or 1% menthol in aqueous cream for symptomatic relief, as suggested by the American College of Allergy, Asthma, and Immunology 1, 2
Identify and eliminate triggering factors including NSAIDs, aspirin, codeine, overheating, stress, and alcohol 1, 2, 3

If urticaria presents with signs of anaphylaxis, immediately administer intramuscular epinephrine 0.5 mL of 1:1000 solution (500 µg) into the anterolateral thigh, as recommended by the American Heart Association 1, 2

Consider omalizumab 300 mg subcutaneously every 4 weeks as second-line treatment for refractory cases, as recommended by the Journal of Allergy and Clinical Immunology 4, 3
Allow up to 6 months to evaluate response before considering alternatives 4, 3

For patients who do not respond to high-dose antihistamines and omalizumab, cyclosporine 4 mg/kg daily for up to 2 months can be considered, though this requires careful monitoring, as recommended by the Journal of Allergy and Clinical Immunology 4, 3
Monitor blood pressure and renal function (blood urea nitrogen and creatinine) every 6 weeks due to risks of hypertension and renal failure 4, 3